Clinical Trials Overview
Clinical research touches every person’s life on a regular basis. It plays an important role in moving medical science and improving the public’s health. According to the U.S. Census Bureau, more than half of all Americans are taking prescription medications at the present time. Most Americans report routinely using over-the-counter medications. All medicines, both prescription and over-the-counter, have gone through clinical testing, involving people who have volunteered to take part in a clinical trial, also known as a research study. All of today’s successful treatments for cancer are based on results of past clinical trials. Because of progress made through clinical trials, people treated for cancer are living longer.
As one of the National Cancer Institute’s designated cancer centers, the Cancer Institute of New Jersey is able to provide access to clinical trials not available at other hospitals, clinics or doctor’s offices. The Cancer Institute currently enrolls more than 3,000 patients in clinical trials or approximately 15 percent of all its new adult cancer patients and approximately 70 percent of all pediatric cancer patients on clinical trials. Enrollment in clinical trials nationwide is fewer than five percent of all adult cancer patients. The Cancer Institute of New Jersey is committed to finding the latest and best treatment options for cancer patients through clinical trials.
- Visit the National Institutes of Health's "NIH Clinical Research Trials and You" website.
- Read the article entitled "The Importance of Cancer Clinical Trials"
- View the video below to learn how to understand cancer clinical trials.
Understanding Cancer Clinical Trials
Learn about clinical trials with CINJ's Eric Singer, MD, MA
Clinical Trials News
Clinical Trial Studies Combination of ALS and Kidney Cancer Drugs for Melanoma Use
Research is underway that aims to determine safe dosing levels for the drugs known as riluzole and sorafenib when used together in the treatment of patients with melanoma. Cancer Institute of New Jersey studies of riluzole, which is approved by the United States Food and Drug Administration (FDA) for the treatment of ALS -- or Lou Gehrig's disease -- have shown evidence of tumor shrinkage in melanoma patients. Sorafenib, an FDA-approved drug used to treat kidney cancer and a form of liver cancer, is considered a "targeted therapy" that has been shown to slow the spread of cancer cells. Recent laboratory studies at the Cancer Institute have shown a more positive effect in the treatment of melanoma with riluzole and sorafenib together than if either drug were given by itself.
Clinical Trial Focuses on New Immune Therapy in Combination with Standard Treatment for Common Form of Kidney Cancer
Researchers at the Cancer Institute of New Jersey are evaluating whether the standard treatment for a common form of kidney cancer works better by itself or when combined with a certain type of blood cell that comes from a patient’s relative. The Sunitinib Plus Extended Courses of Irradiated Allogeneic Lymphocytes for Patients with Renal Cell Carcinoma -- or SPECIAL -- trial is sponsored by the United States Food and Drug Administration, which also will monitor the study.